Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is over
Hims & Hers stock dropped nearly 10% due to FDA lifting drug shortages for competitor Eli Lilly, while its own semaglutide product remains unaffected.